Takeda and Code Biotherapeutics announced a collaboration agreement to leverage the latter’s proprietary targeted 3DNA non-viral genetic medicine delivery platform for the design and development of gene therapies for rare diseases.
The COVID-19 pandemic has brought to light the incredible power of collaboration in the life science industry. About 40 percent of Pfizer’s portfolio was realized through partnerships, and the pharma giant announced three more collaborative deals on January 10.
Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).
Three months after hearing loss-focused company Akouos secured $105 million in a Series B financing round, the Boston-based company is eying an initial public offering valued at about $100 million.
Astellas Pharma Inc. bought U.S.-based Xyphos Biosciences Inc. to expand the Japanese drugmaker’s immuno-oncology business, a deal worth up to $665 million.
